AstraZeneca Pharmaceuticals LP
NEWS
“We are pleased to see the sustained and meaningful survival benefit of Imfinzi for patients with small cell lung cancer after more than two years median follow up,” said Jose Baselga, Astra Zeneca’s executive vice president, Oncology R&D.
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
The primary endpoint was a statistically significant improvement in progression-free survival for the combination versus platinum-based chemotherapy.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
The company said its combination treatment of Imfinzi (durvalumab) plus tremelimumab, an anti-CTLA4 antibody and Imfinzi on its own, did not improve overall survival in patients with this advanced form of bladder cancer.
AstraZeneca says the overrun is because of the complexity of the construction, inflation and other factors.
Under the license deal, RedHill is paying AstraZeneca $52.5 million up front with another non-contingent payment of $15 million 18 months after the deal closes.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
JOBS
IN THE PRESS